Related Experiment Video

Updated: Aug 9, 2026

Rapid Analysis of Chromosome Aberrations in Mouse B Lymphocytes by PNA-FISH
07:54

Rapid Analysis of Chromosome Aberrations in Mouse B Lymphocytes by PNA-FISH

Published on: August 19, 2014

Loss of p53 impedes the antileukemic response to BCR-ABL inhibition

Hans-Guido Wendel1, Elisa de Stanchina, Enriqué Cepero

  • 1Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA.

Proceedings of the National Academy of Sciences of the United States of America
|May 3, 2006
PubMed

Insights

The tumor suppressor p53 is activated by imatinib in BCR-ABL-expressing cancer cells. Inactivating p53 impedes imatinib response and is linked to resistance in chronic myelogenous leukemia.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Targeted cancer therapies leverage cancer cell dependence on oncogenic mutations.
  • Resistance to targeted therapies is a significant clinical challenge.
  • Imatinib is a targeted therapy for chronic myelogenous leukemia (CML) that inhibits BCR-ABL kinase.

Purpose of the Study:

  • To investigate factors influencing targeted drug action using imatinib as a model.
  • To understand the role of p53 in the response to imatinib in BCR-ABL-expressing cells.

Main Methods:

  • Studied imatinib's effects on murine cells and leukemias with BCR-ABL expression.
  • Assessed p53 activation in response to imatinib and BCR-ABL kinase inhibition.
  • Evaluated the impact of p53 inactivation on imatinib efficacy in vitro and in vivo.

Main Results:

  • Imatinib selectively activates p53 in BCR-ABL-expressing cells via BCR-ABL kinase inhibition.
  • p53 inactivation hinders imatinib response without affecting BCR-ABL kinase inhibition.
  • p53 mutations correlate with imatinib resistance in some human CML cases.

Conclusions:

  • p53 is a key determinant of response to oncogene inhibition therapy.
  • p53 inactivation represents a mechanism for acquired resistance to targeted cancer therapies like imatinib.
  • Understanding p53's role can inform strategies to overcome resistance in CML and other cancers.

More Related Videos

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence04:56

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence

Published on: December 30, 2025

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...